SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported): December 13, 2016
Proteon Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
|(State or Other Jurisdiction of Incorporation)||(Commission File Number)||(I.R.S. Employer Identification Number)|
|200 West Street, Waltham, MA 02451|
|(Address of Principal Executive Offices) (Zip Code)|
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
|Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:|
| ||[ ]|| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
| ||[ ]|| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
| ||[ ]|| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
| ||[ ]|| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Throughout this Current Report on Form 8-K, the terms “we,” “us,” “our”, “Company” and “Proteon” refer to Proteon Therapeutics, Inc.
Item 7.01. Regulation FD Disclosure.
On December 13, 2016, the Company issued a press release announcing the release of data from its first Phase 3 clinical trial with investigational vonapanitase, PATENCY-1. The press release is attached to this Current Report as Exhibit 99.1 hereto and is incorporated herein by reference.
Further, officers and representatives of the Company will present to various investors and stockholders beginning December 13, 2016 using the presentation materials furnished as Exhibit 99.2 hereto and which are incorporated herein by reference.
The information in this report (including Exhibits 99.1 and 99.2) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
|99.1||Press Release, dated December 13, 2016, issued by Proteon Therapeutics, Inc.|
|99.2||Presentation materials to be used by officers and other representatives of Proteon Therapeutics, Inc.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ||Proteon Therapeutics, Inc.|
| || || |
| || |
|Date: December 13, 2016||By: ||/s/ George A. Eldridge |
| || ||George A. Eldridge|
| || ||Senior Vice President & Chief Financial Officer|
| || |
|Exhibit No.|| ||Description|
| || || |
|99.1|| ||Press Release, dated December 13, 2016, issued by Proteon Therapeutics, Inc. || || |
|99.2|| ||Presentation materials to be used by officers and other representatives of Proteon Therapeutics, Inc. |